Chronic Schizophrenia

Neurology
3
Pipeline Programs
2
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
OXYGEN, USPApproved
oxygen
Unknown Company
inhalation2018

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
1
oxygenPhase 31 trial
Active Trials
NCT00525863Unknown20Est. Dec 2009
Newron Pharmaceuticals
1 program
1
NW-3509APhase 21 trial
Active Trials
NCT02624167CompletedEst. Jan 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance Pharmaceuticalsoxygen
Newron PharmaceuticalsNW-3509A

Clinical Trials (2)

Total enrollment: 20 patients across 2 trials

Oxygen Therapy in Schizophrenia

Start: Jan 2008Est. completion: Dec 200920 patients
Phase 3Unknown

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

Start: Dec 2015Est. completion: Jan 2017
Phase 2Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space